What does this research mean for the field?

Off-label use of JAK inhibitors demonstrates promising therapeutic potential across a broad spectrum of refractory dermatological diseases, although current evidence is primarily limited to uncontrolled case reports and series. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the therapeutic outcomes and safety of off-label Janus kinase (JAK) inhibitor administration across refractory dermatologic diseases.

September 14, 2026Journal of Dermatological TreatmentOpen Access

The emerging applications of JAK inhibitors in dermatology – a systematic review

View Full Paper

Ask AI

Bookmark

Authors

KAKhalid M. A. AhmedUniversity of Leeds AAAlaa I. AlnajdawiUniversity of Jordan NKNithikka Senthil KumarUniversity of Leeds

Discussion

Member takes

Implication

Systematic review demonstrates clinical improvement with off-label Janus kinase inhibitors in refractory skin diseases, suggesting therapeutic promise despite reliance on uncontrolled case data.

Key Points

To assess the therapeutic outcomes and safety of off-label Janus kinase (JAK) inhibitor administration across refractory dermatologic diseases.
Searched MEDLINE, Embase, and Web of Science from database inception through October 1, 2025, for off-label JAK inhibitor use in non-approved dermatologic indications.
Identified 277 eligible studies (210 case reports, 55 case series, and 12 retrospective studies) comprising a total of 764 patients.
Narratively synthesized outcome data across disease families due to marked clinical heterogeneity.
Clinical benefit occurred in 725/764 patients (94.88%), with complete or near-complete responses in 209/764 (27.35%) and significant or partial improvement in 516/764 (67.53%).
Off-label use focused primarily on lichenoid, neutrophilic, and granulomatous dermatoses; 35 patients (4.58%) experienced no clinical change and 4 (0.52%) experienced disease worsening.
A total of 154 adverse events were recorded—most frequently with tofacitinib—including 6 serious adverse events and 25 leading to treatment discontinuation.

Cite This Study

Ahmed et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3580926e14a848b232b https://doi.org/10.1080/09546634.2026.2714664

View Full Paper

Ask AI

Bookmark

Implication

Systematic review demonstrates clinical improvement with off-label Janus kinase inhibitors in refractory skin diseases, suggesting therapeutic promise despite reliance on uncontrolled case data.

The emerging applications of JAK inhibitors in dermatology – a systematic review

Discussion

Member takes

Implication

Key Points

Cite This Study

The emerging applications of JAK inhibitors in dermatology – a systematic review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider